Revenue of $10.1 million
229 authorizations and orders, highest number this year
Reiterates full year revenue guidance of $40 million to $42 million
Conference call begins today at 4:30pm Eastern time
BURLINGTON, Mass. (November 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. Read more.